Partner Joseph Re was quoted in “Supreme Court Case Pits Inventors Against Their Former Employers,” an article published by Bloomberg Law

In the Managing IP article “Counsel Mull Remand Likelihood After Dewberry v Dewberry Arguments,” litigation partner Brian Horne offered his perspective on the latest developments in a highly anticipated trademark...

On March 29, 2023, the Solicitor General of the United States asked the Supreme Court to review a Federal Circuit judgment in a Hatch-Waxman case between Teva and GSK. In its decision below, the Federal Circuit held that Teva could be held liable for inducement based on language in its “skinny label” and reinstated a $235 million jury award to GSK that the district court had set aside. The question at the heart of the case—as framed by Teva—is: “If a generic drug’s FDA-approved label carves out all of the language that the brand manufacturer has identified as covering its patented uses, can the generic manufacturer be held liable on a theory that its label still intentionally encourages infringement of those carved-out uses?”

In the article “High Court Case on US Trademark Law’s Limits Stretches Beyond IP,” published by Bloomberg Law, partner and co-chair of Knobbe Martens’ trademark practice group Jeff Van Hoosear...